Lilly's Tirzepatide Now Available on E-commerce Platforms; MicroPort NeuroTech's 3D Electrodetachable Coil Receives NMPA Approval
PDBio
Peptide Innovation Drug Developer
HJ Science
Innovative Small Molecule Drug Research, Development, and Production
NovaBridge Biosciences
Biological Agent Developer
Amino Observation - Original Production by the Innovative Drug Team
Author | Huang Kai
GLP-1 drugs have been successively listed on e-commerce platforms.
On December 25, several e-commerce platforms now offer diagnosis and medication services for Eli Lilly's tirzepatide (brand name: Mounjaro).
The indications for tirzepatide include diabetes and weight loss. Currently, the prices vary among different merchants on the platform. Eli Lilly China stated that this drug is a self-funded medication, and the specific price can be referred to the pricing of major pharmaceutical institutions.
Multiple medical device products have obtained registration certificates.
On December 25, according to the NMPA website, products such as MicroPort NeuroTech's three-dimensional electrically detachable coil, and Dabo Medical's dynamic hip and condylar compression osteosynthesis plate systems received registration approval.
However, the result for Ruishen An Medical's implantable rechargeable spinal cord stimulator was: not registered.
In the past day, what hot topics in the pharmaceutical markets at home and abroad are worth paying attention to? Let Amino take you to explore.
/ 01 /
Market Express
1) Eli Lilly's Tirzepatide Now Available for Purchase on E-commerce Platforms
On December 25, several e-commerce platforms in China now offer diagnosis and prescription services for Eli Lilly's tirzepatide (brand name: Mounjaro). The indications for tirzepatide include diabetes and weight management, with varying prices among different merchants on the platform. Eli Lilly China stated that this drug is a self-pay medication, and specific pricing should refer to the pricing of major pharmaceutical institutions.
/ 02 /
Pharmaceutical News
1) PDBio's PD-DP-008 Gel Receives Clinical Approval
On December 25, according to the CDE official website, PDBio's PD-DP-008 gel obtained clinical approval and is planned to be studied for the treatment of acne vulgaris.
2) HJ Science's HJ787 Ointment Receives Clinical Approval
On December 25, according to the CDE website, HJ Science's HJ787 Ointment received clinical approval and is proposed to initiate research for the treatment of acne.
3) REGENECORE's RC1416 Injection Receives Clinical Approval
On December 25, according to the CDE website, REGENECORE's RC1416 injection has been granted clinical approval and is proposed to initiate research for the treatment of moderate to severe atopic dermatitis.
4) Tianjing Biotechnology (Shanghai) Co., Ltd.'s TJ037130 Injection Receives Clinical Approval
On December 25, according to the CDE official website, Tianjing Biotechnology's TJ037130 injection has been granted clinical approval for the proposed study to treat advanced solid tumors.
5) Haohai Bio LKR202 Injection Receives Clinical Approval
On December 25, according to the CDE website, Haohai Biotech's LKR202 injection has been granted clinical approval for the proposed study on treating osteoarthritis.
6) Yingli Pharmaceutical's AK-1286 Tablets Receive Clinical Approval
On December 25, according to the CDE website, Yingli Pharmaceutical's AK-1286 tablet received clinical approval and is proposed to initiate research for the treatment of advanced solid tumors.
7) VSA012 Injection from Viya Zhen Bio Obtains Clinical Approval
On December 25, according to the CDE official website, ViaGen Bio's VSA012 injection has been granted clinical approval for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH).
8) AAV Gene Therapy Product of Fangtuo Bio Receives FDA Approval for Phase II Clinical Trial
On December 25, Fount Bio announced that its new AAV gene therapy product, FT-003 injection, for the treatment of diabetic macular edema, has received FDA approval to proceed with Phase II clinical trials.
/ 03 /
Instrument Tracking
1) RESONANCE Medical's Implantable Rechargeable Spinal Cord Stimulator Not Registered
On December 25, according to the NMPA website, Ruishen An Medical's implantable rechargeable spinal cord stimulator was not registered.
2) Minimally Invasive Shenzhou Three-Dimensional Electrolytic Detachable Coil Obtains Registration Approval
On December 25, according to the NMPA website, MicroPort NeuroTech's three-dimensional electrically detachable coil received registration approval.
3) Daobo Medical's Dynamic Hip and Condylar Compression Osteosynthesis Plate System Receives Registration Approval
On December 25, according to the NMPA website, Dabo Medical's dynamic hip and condylar compression bone plate system received registration approval.
PS: Welcome to scan the QR code below to add the WeChat ID of AminoGenius for communication.
